繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Rafael And Cyclo Therapeutics Have Agreed To Combine To Focus Trappsol Cyclo For Niemann-pick Disease Type C1

2024-08-22 18:52

On consummation of the merger, Rafael will issue Class B shares to Cyclo Therapeutics' shareholders, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings at its cash value combined with the value of its marketable securities and certain other investments less certain current liabilities

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。